Dr. Rose's translational research interests antimicrobial pharmacology, resistance, and host-pathogen interactions.  His laboratory incorporates translational modeling systems to simulate antimicrobial exposures against multi-drug resistant pathogens. These studies are used to evaluate optimal antibiotic activity, antibiotic penetration into simulated infections, the development of antibiotic resistance, and virulence  In addition, his laboratory incorporates molecular biology and fundamental mechanism studies of the host-pathogen interface. His clinical studies involve the impact of patient innate immune responses and bacterial virulence on the treatment outcome of invasive infections.

Warren Rose is a faculty member in the School of Pharmacy, Pharmacy Practice Division.  He also has an adjunct affiliate faculty appointment in the Department of Medicine, Division of Infectious Diseases.  He holds clinical appointments within the Departments of Pharmacy at UW Health and the William S. Middleton VA in Madison.  He is the recipient of the Society of Infectious Diseases Young Investigator of the Year Award and the American College of Clinical Pharmacy - Infectious Diseases Distinguished Investigator Award.  Dr. Rose is an appointed member to the Editorial Board of Antimicrobial Agents and Chemotherapy since 2016. He is a Fellow of both the Infectious Diseases Society of America and the American College of Clinical Pharmacy.  

Education:

• PharmD  - Butler University
• Residency - Rush University Medical Center
• Fellowship - Wayne State University, Anti-Infective Research Laboratory
• MPH - UW-Madison

Course Coordinator

• PHMPRC 656 Pharmacotherapy IV - Infectious Diseases and Oncology Therapeutics
• PHMPRC 560 Seminars in Antimicrobial Stewardship 
• PHMPRAC 559: Introduction to Infectious Diseases Pharmacotherapy (online)

Lecturer

• PHMSCI 623 Pharmacology III
• PHMSCI 540 Drug Delivery
• PHMSCI 645 Biotechnology & Pharmacogenomics
• PHMPRC 560 Seminars in Antimicrobial Stewardship 
• PHMPRC 559 Introduction to Infectious Diseases Pharmacotherapy (online)
• PHMPRC 570 Drug Literature Evaluation

Clerkship Rotation

• Acute Care Elective 760 - UW Health
• Clinical Research and Pharmacy Investigation 769

Complete list can be found at PubMed

Publications since 2019

• Rose W, Fantl M, Geriak M, Nizet V, Sakoulas G. Current Paradigms of Combination therapy in Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia: Does it Work, Which Combination and For Which Patients? Clin Infect Dis 2021 in press.
• Sun J, Uchiyama S, Olson J, Morodomi J, Cornax I, Ando N, Kohno Y, Kyaw M, Aguilar B, Haste NM, Kanaji S, Kanaji T, Rose WE, Sakoulas G, Marth JD, Nizet V. Repurposed Drugs Block Toxin-Driven Platelet Clearance by the Hepatic Ashwell-Morell Receptor to Clear Staphylococcus aureus Sci Transl Med 2021 Mar 24;13(586):eabd6737. doi: 10.1126/scitranslmed.abd6737; PMID: 33762439.
• Klatt ME, Schulz LT, Fleischman D, Fox BC, Burke S, Grinder D, Rose WE, Lepak AJ, Andes DR. Implementation of telehealth antimicrobial stewardship through an academic medical center-community hospital partnership. Am J Health Syst Pharm. 2021 in press.
• Schulz LT, Dilworth TJ, Rose WE. Pragmatic application of area under the concentration-time curve monitoring from the 2020 vancomycin consensus guidelines. Am J Health Syst Pharm. 2021 in press. doi: 10.1093/ajhp/zxab121; PMID: 33764404. PMID: 33764404
• Budi N, Godfrey JJ, Safdar N, Shukla SK, Rose WE. Omadacycline compared to vancomycin when combined with germinants to disrupt the life cycle of Clostridioides difficile. Antimicrob Agents Chemother. 2021 Mar 1:AAC.01431-20. doi: 10.1128/AAC.01431-20. PMID: 33649111. 
• Dilworth TJ, Schulz LT, Rose WE. Vancomycin Advanced Therapeutic Drug Monitoring: An Exercise in Futility or Virtuous Endeavor to Improve Drug Efficacy and Safety? Clin Infect Dis. 2020 Sep 8:ciaa1354. doi: 10.1093/cid/ciaa1354. Epub ahead of print. PMID: 32898221.
• Budi N, Safdar N, Rose WE. Treatment issues in recurrent Clostridioides difficile infections and the possible role of germinants, FEMS Microbes 2020 Sept 1(1), xtaa001, doi: 10.1093/femsmc/xtaa001.
• Varela MC, Roch M, Taglialegna A, Long SW, Saavedra MO, Rose WE, Davis JJ, Hoffman LR, Hernandez RE, Rosato RR, Rosato AE. Carbapenems drive the collateral resistance to ceftaroline in cystic fibrosis patients with MRSA. Commun Biol. 2020 Oct 22;3(1):599. doi: 10.1038/s42003-020-01313-5. PMID: 33093601.
• Berti A, Rose W, Nizet V Sakoulas G. Antibiotics and Innate Immunity: A Cooperative Effort Towards the Successful Treatment of Infections. Open Forum Infect Dis. 2020;7(8): ofaa302. doi:10.1093/ofid/ofaa302. PMID: 32818143
• Jenson RE, Baines SL, Howden BP, Mishra NN, Farah S, Lew C, Berti AD, Shukla SK, Bayer AS, Rose WE. Prolonged exposure to β-lactam antibiotics reestablishes susceptibility of daptomycin-nonsusceptible Staphylococcus aureus to daptomycin. Antimicrob Agents Chemother. 2020;64(9):e00890-20. Published 2020 Aug 20. doi:10.1128/AAC.00890-20. PMID: 32601160 '
• Wozniak JM, Olson J, Caldera JR, Mills R, Carrillo-Terrazas M, Tsai C, Vargas F, Dorrestein P, Liu G, Nizet V, Sakoulas G, Rose W, Gonzalez DJ. Mortality Risk Profiling of Staphylococcus aureus Bacteremia by Multi-omic Serum Analysis Reveals Early Predictive and Pathogenic Molecular Signatures. Cell 2020; 182, 1311–1327. doi: 10.1016/j.cell.2020.07.040. PMID: 32888495.
• Carter TC, Ye Z, Schrodi SJ, Ivacic LC, Budi N, Rose WE, Shukla SK. Association of Variants in Selected Genes Mediating Host Immune Response with Duration of Staphylococcus aureus Genes and Immunity 2020;21(4):240-248. doi:10.1038/s41435-020-0101-0. PMID: 32507857
• Rose WE, Hutson PR. A two-dose oritavancin regimen using pharmacokinetic estimation analysis.  Drugs Real World Outcomes. 2020;7(Suppl 1):36-40. doi:10.1007/s40801-020-00188-6.  PMID: 32588386
• Volk CF, Burgdorf S, Edwardson G, Nizet V, Sakoulas G, Rose WE. IL-1β and IL-10 Host Responses in Patients with Staphylococcus aureus Bacteremia Determined by Antimicrobial Therapy.  Clin Infect Dis. 2020 Jun 10;70(12):2634-2640.  PMID:  31365924.
• Heil EL, Aitken SL, Nix DE, Drew R, Rose WE, Davis SL, Justo JA, Fish DN, Pogue JM. Insights from the Society of Infectious Diseases Pharmacists on the Infectious Diseases Society of America Position Paper for Recommended Revisions to the National SEP-1 Sepsis Quality Measure. 2020; 40(4): 368-371.  PMID: 32277525
• Jahanbakhsh S, Singh N, Yim J, Kabriaei R, Smith JR, Lev K, Tran TT, Rose WE, Arias CA, Rybak MJ. Impact of Daptomycin dose exposure alone or in combination with β- lactams or rifampin against vancomycin-resistant Enterococci (VRE) in an in vitro biofilm model. Antimicrob Agents Chemother. 2020 Feb 24. pii: AAC.02074-19. PMID: 32094136
• Kim J, Bishop AR, Squire M, Rose WE Ploeg H. Mechanical, Elution, and Antibacterial Properties of Simplex Bone Cement Loaded-with Vancomycin. J Mech Behav Biomed Mater. 2020; 103:103588. doi:10.1016/j.jmbbm.2019.103588. PMID: 32090917
• Shukla SK, Carter T, Ye Z, Pantrangi M, Rose WE. Modeling of effective antimicrobials to reduce Staphylococcus aureus virulence gene expression using a two-compartment hollow fiber infection model. Toxins 2020 12(2):69. Published 2020 Jan 22. doi:10.3390/toxins12020069. PMID: 31979087
• Rose WE, Bienvenida AM, Xiong YQ, Chambers HF, Bayer AS, Ersoy SC. Ability of Bicarbonate Supplementation to Sensitize Selected Methicillin-Resistant Staphylococcus aureus (MRSA) Strains to β-Lactam Antibiotics in an Ex Vivo Simulated Endocardial Vegetation Model. Antimicrob Agents Chemother. 2020; 64(3): e02072-19. doi:10.1128/AAC.02072-19. PMID: 31844004
• Miller LS, Fowler VG, Shukla SK, Rose WE, Proctor RA. Development of a vaccine against Staphylococcus aureus invasive infections: Evidence-based on human immunity, genetics, and bacterial evasion mechanisms. FEMS Microbiol Rev. 2020; 44(1): 123–153. doi:10.1093/femsre/fuz030. PMID: 31841134
• Pagels C. McCreary EK, Rose WE, Dodds Ashley ES, Bookstaver BB, Dilworth TJ. Designing Antimicrobial Stewardship Interventions to Enhance Scientific Dissemination. J Am Coll Clin Pharm 2020; 3: 109– 115.  https://doi.org/10.1002/jac5.1164
• McCreary EK, Kullar R, Geriak M, Zasowski EJ, Rizvi K, Schulz LT, Ouellette K, Vasina L, Haddad F, Rybak MJ, Zervos MJ, Sakoulas G, Rose WE. Multicenter Cohort of Patients with Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia Receiving Daptomycin plus Ceftaroline Compared to Other MRSA Treatments. Open Forum Infect Dis. 2019; 7(1): ofz538. Published 2019 Dec 31. doi:10.1093/ofid/ofz538. PMID: 31938716    
• Sakoulas G, Geriak M, Haddad F, Rose W, LaPlante KL, Zervos MJ, Kullar R, Nizet V. Reply to Kalil et al., "Is Daptomycin plus Ceftaroline Associated with Better Clinical Outcomes than Standard of Care Monotherapy for Staphylococcus aureus Bacteremia?" Antimicrob Agents Chemother 2019; 63(11): e01347-19.  PMID: 31640978.
• Schulz LT, Kim SY, Hartsell A, Rose WE. Antimicrobial Stewardship During a Time of Rapid Antimicrobial Development: Potential Impact on Industry for Future Investment.  Diagn Microbiol Infect Dis. 2019;95(3):114857. PMID: 31327622.
• Legenza L, Barnett S, Lacy J, Desotell N, Eibergen A, Rose W. Geographic mapping of Escherichia coli susceptibility to develop a novel clinical decision support tool. Antimicrob Agents Chemother 2019; 63(6). pii: e00048-19. PMID: 30936105.
• Geriak M, Haddad F, Rizvi K, Rose W, Kullar R, LaPlante K, Yu M, Vasina L, Ouellette K, Zervos M, Nizet V, Sakoulas G. Clinical Data on Daptomycin Plus Ceftaroline Versus Standard of Care Monotherapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Antimicrob Agents Chemother 2019; 63(5). pii: e02483-18. PMID: 30858203.